Advertisement

Volume 133, Issue 19

 

 

May 9, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: A role for megakaryocytes in immunity. See the article by Campbell et al.

Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3
In a Plenary Paper, the investigators demonstrate that megakaryocytes, mainly recognized for their role in the generation of platelets, are also capable of preventing the spread of viral infection, indicating a role in immunity.


Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab
After nearly 4 years of follow-up, the authors present impressive sustained, progression-free, and overall survival benefits following the use of the Bruton tyrosine kinase inhibitor ibrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.


Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ
In this study, the investigators shed light on the mechanism of pancytopenia in inflammation, a long-standing clinical observation lacking an explanation. Interferon- γ (IFN- γ), a mediator of the inflammatory response, suppresses hematopoietic stem and progenitor cell function by binding to thrombopoietin, thereby blocking its signaling via its own c-MPL receptor.


Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice
Imagine a scenario in which defective or malignant hematopoietic stem cells (HSCs) are depleted and replaced by healthy HSCs without hematologic or systemic side effects. These studies show that selective hematopoietic stem cell transplantation might become a clinical reality.


Access to emergency departments for acute events and identification of sickle cell disease in refugees
The authors describe how the recent refugee crisis affects southern Europe and how medical care is provided to refugees entering Italy with unrecognized hemoglobin disorders.


Fostamatinib for the treatment of chronic immune thrombocytopenia
In this Blood Spotlight, the authors concisely review the mechanism of action and therapeutic value of the spleen tyrosine kinase inhibitor fostamatinib for chronic immune thrombocytopenia.


View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.